Prime Medicine Receives New Zealand CTA Clearance for PM577a in Wilson Disease
CAMBRIDGE, Mass., June 18, 2026 Prime Medicine, Inc. announced that New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe)...
gene editing
Advertisement
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Eti-cel Data at EHA 2026
NEW YORK, NY, June 11, 2026 Cellectis announced final Phase 1 results from the BALLI-01 clinical trial evaluating lasme-cel,...
Anocca Doses First Patients with KRAS-Targeted TCR-T Therapy
SÖDERTÄLJE, Sweden, June 11, 2026 Anocca AB announced the successful dosing of the first patients in its VIDAR-1 clinical...
Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
Precision BioSciences Reveals Breakthrough HBV Data
DURHAM, N.C., May 27, 2026 Precision BioSciences announced new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV,...
Advertisements
Lilly’s VERVE-102 Shows Durable LDL-C Reduction
Indianapolis, Indiana, USA, May 25, 2026 Eli Lilly and Company has announced positive Phase 1b clinical results for VERVE-102,...
Tenaya Gene Therapy Shows Strong Arrhythmia Reduction in ARVC Trial
SOUTH SAN FRANCISCO, Calif., May 15, 2026 Tenaya Therapeutics reported encouraging interim Phase 1b/2 clinical data for TN-401, its...
Mission Bio Unveils Single-Cell CRISPR T Cell Data
SOUTH SAN FRANCISCO, Calif., May 2026 Mission Bio announced new data demonstrating the power of its Targeted Single-Cell DNA+RNA...
BioMarin VOXZOGO Shows Long-Term Growth Benefits
San Rafael, California, United States | May 2, 2026 BioMarin Pharmaceutical Inc. has presented new long-term clinical data for...
Scribe Therapeutics Showcases CRISPR and STX-1150 Data
Alameda, California, United States | April 30, 2026 Scribe Therapeutics has announced significant advancements in its engineered CRISPR gene...
Advertisement
